Related Experiment Video
Updated: Feb 24, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.9K
Integrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma
Kelly E Regan1, Philip R O Payne2, Fuhai Li1
1Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Summary
SynGeNet, a new computational method, accurately predicts synergistic drug combinations by integrating gene expression data and network analysis. This approach enhances the discovery of effective cancer therapies and overcomes drug resistance.
Area of Science:
- Computational biology
- Pharmacogenomics
- Systems biology
Background:
- Developing effective drug combinations is crucial for improving treatment durability and preventing drug resistance.
- Computational methods are needed to efficiently predict synergistic drug combinations.
Purpose of the Study:
- To present SynGeNet, a novel computational method for predicting synergistic drug combinations.
- To evaluate SynGeNet's performance against existing transcriptomics-based tools.
Main Methods:
- Integrating transcriptomics data (disease and drug z-score profiles) with network mining algorithms.
- Comparing SynGeNet with other tools using validated drug combinations in melanoma cell lines (BRAF-mutant, NRAS-mutant, combined).
Main Results:
- SynGeNet outperformed existing tools in predicting validated drug combinations and single agents.
- Performance decreased without network construction and improved with matched-genotype validation data.
Conclusions:
- Network mining and genomic features from transcriptomics data improve drug combination predictions.
- SynGeNet offers a promising approach for identifying effective combination therapies.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
01:29Pharmacogenetics and Pharmacogenomics: Overview
51
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51